Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers....

Full description

Saved in:
Bibliographic Details
Published in:BMC Res Notes
Main Authors: Vallo, Stefan, Michaelis, Martin, Gust, Kilian M., Black, Peter C., Rothweiler, Florian, Kvasnicka, Hans-Michael, Blaheta, Roman A., Brandt, Maximilian P., Wezel, Felix, Haferkamp, Axel, Cinatl, Jindrich
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://ncbi.nlm.nih.gov/pubmed/27677700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-016-2256-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items